Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 4, 2015, Pages 519-527

  Abenavoli, Ludovico ^a   Greco, Marta ^a   Nazionale, Immacolata ^a   Peta, Valentina ^a   Milic, Natasa ^b   Accattato, Francesca ^a   Foti, Daniela ^a   Gulletta, Elio ^a   Luzza, Francesco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Antioxidant; BMI; Insulin resistance; Liver steatosis; Metabolism

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL PLUS SILIBININ PLUS PHOSPHATIDYLCHOLINE; CHOLESTEROL; PHOSPHATIDYLCHOLINE; SILIBININ; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; SILYMARIN;

ADULT; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GLUCOSE METABOLISM; HUMAN; LIPID HOMEOSTASIS; LIPID STORAGE; MEDITERRANEAN DIET; MULTICENTER STUDY; NONALCOHOLIC FATTY LIVER; OBESITY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WAIST CIRCUMFERENCE; BLOOD; COMPARATIVE STUDY; DIET SUPPLEMENTATION; DIET THERAPY; ITALY; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; TIME; TREATMENT OUTCOME;

ADULT; BIOMARKERS; BODY MASS INDEX; CHOLESTEROL; DIET, MEDITERRANEAN; DIETARY SUPPLEMENTS; HUMANS; ITALY; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OVERWEIGHT; PHOSPHATIDYLCHOLINES; PROSPECTIVE STUDIES; SILYMARIN; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VITAMIN E; WAIST CIRCUMFERENCE;

EID: 84924414123     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1004312     Document Type: Review

References (51)

1. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-16
2. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:511-31
3. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-50
4. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;171-80
5. Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013;59:859-71
6. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42:320-30
7. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25
8. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5
9. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 2013;19:3375-84
10. Loria P, Adinolfi L.E, Bellentani S, et al. NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42:272-82
11. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-112
12. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007;46:1387-91
13. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012;30(2):158-62
14. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-5
15. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-46
16. Abenavoli L, Scarpellini E, Rouabhia S, et al. Probiotics in non-alcoholic fatty liver disease: which and when. Ann Hepatol 2013;12:357-63
17. Scarpellini E, Cazzato A, Lauritano C, et al. Probiotics: which and when? Dig Dis 2008;26:175-82
18. Compare D, Coccoli P, Rocco A, et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012;22:471-6
19. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84
20. Farrell GC, Chitturi S, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22:775-7
21. Fan JG, Jia JD, Li YM, et al. Chinese Association for the Study of Liver Disease. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis 2011;12:38-44
22. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23
23. Greco M, Chiefari E, Montalcini T, et al. Early effects of a hypocaloric, mediterranean diet on laboratory parameters in obese individuals. Mediators Inflamm 2014;2014:750860
24. De Lorenzo A, Noce A, Bigioni M, et al. The effects of Italian Mediterranean organic diet (IMOD) on health status. Curr Pharm Des 2010;16:814-24
25. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:1189-96
26. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res 2010;24:1423-32
27. Abenavoli L, Bellentani S. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? Expert Rev Gastroenterol Hepatol 2013;7:677-9
28. Serviddio G, Bellanti F, Giudetti AM, et al. A silybin-phospholipids complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Exp Ther 2010;332:922-32
29. Milić N, Milosević N, Suvajdzić L, et al. New therapeutic potentials of milk thistle (Silybum marianum). Nat Prod Commun 2013;8:1801-10
30. Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med 2012;52:1658-65
31. Di Daniele N, Petramala L, Di Renzo L, et al. Body composition changes and cardiometabolic benefits of a balanced Italian Mediterranean Diet in obese patients with metabolic syndrome. Acta Diabetol 2013;50:409-16
32. De Lorenzo A, Alberti A, Andreoli A, et al. Food habits in a southern Italian town (Nicotera) in 1960 and 1996: still a reference Italian Mediterranean diet?Diabetes Nutr Metab 2011;14:121-5
33. Loguercio C, Federico A, Trappoliere M, et al. The effect of a silybin-vitamin ephospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007;52:2387-95
34. Ascaso JF, Pardo S, Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003;26:3320-5
35. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Human Kinetics; Champaing, IL: 1998. p. 121-33
36. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;12:2708-15
37. Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. Gastroenterology 2010;10:98
38. Xiao J, Fai So K, Liong EC, Tipoe GL. Recent advances in the herbal treatment of non-alcoholic Fatty liver disease. J Tradit Complement Med 2013;3(2):88-94
39. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904
40. Chalasani N, Younossi Z, Lavine JE, et al. American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609
41. El-Sheikh N, HNA E-F. Counteracting methionine choline-deficient diet-induced fatty liver by administration of turmeric and silymarin. J Appl Sci Rese 2005;7(12):1812-20
42. Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009;9(4):265-70
43. Federico A, Trappoliere M, Tuccillo C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006;55:901-2
44. McCarty MF. Potential utility of natural polyphenols for reversing fat-induced insulin resistance. Med Hypotheses 2005;64(3):628-35
45. Velussi M, Cernigoi AM, De Monte A, et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997;26:871-9
46. Hajaghamohammadi AA, Ziaee A, Raflei R. The efficacy of silymarin in decreasing transaminase activities in nonalcoholic fatty liver disease. A randomized controlled clinical trial. Hepat Mon 2008;8:191-5
47. Fraser A, Abel R, Lawlor DA, et al. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia 2008;51:1616-22
48. Tzima N, Pitsavos C, Panagiotakos DB, et al. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. Nutr Metab (Lond) 2009;6:30
49. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013;59:138-43
50. Pérez-Guisado J, Muñoz-Serrano A. The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. J Med Food 2011;14:677-80
51. Grattagliano I, Diogo CV, Mastrodonato M, et al. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. World J Gastroenterol 2013;19:3007-17